Clinical trial of efficacy for tocilizumab in systemic sclerosis and sclerodermatous chronic GVHD

Clinical trial of efficacy for tocilizumab in systemic sclerosis and sclerodermatous chronic GVHD - Clinical trial of efficacy for tocilizumab in systemic sclerosis and sclerodermatous chronic GVHD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020389

Enrollment

Registered

2016-01-06

Start date

2015-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients with systemic sclerosis or sclerodermatous chronic GVHD.

Interventions

treatment with tocilizumab duration: 20 weeks dosage: 8mg/kg times: 6 times Frequency: every 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: There is no natural remission of skin sclerosis.

Exclusion criteria

Exclusion criteria: 1.Patients with a history of shock or hypersensitivity to this drug. 2.Patients who are complicated by infectious diseases. 3.Patients with a history of myocardial infarction or unstable angina. 4.Patients with reduced severe bone marrow function. 5.Women who may be pregnant or pregnant. 6.Lactating women

Design outcomes

Primary

Measure	Time frame
Evaluate skin score at 0, 1, 4, 8, 12, 16, 20, 24 weeks after treatment.	—

Countries

Japan

Contacts

Public ContactTakashi Matsushita

Kanazawa University Hospital Dermatology

t-matsushita@med.kanazawa-u.ac.jp0762652343

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026